Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Mohammadhossein Behnam Ghasemzadeh
Marquette University, Department: Other Basic Sciences
Should you be removed from our database? Contact us at [email protected]. Read more below.
AviMed Pharmaceuticals
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Ghasemzadeh serves as the Chief Scientific Officer and President of AviMed and holds equity interest in the company. The proposed work to be conducted via the R21 has scientific overlap with the mission of AviMed.
KNCQ Potassium Channels and Schizophrenia
Schizophrenia is a chronic mental disorder with devastating and disruptive personal, family, and social consequences, which affects about 1.1% of the world population above 18 years of age. In any given year, more than 2.4 million Americans and about 52 million individuals in the world suffer from pathologies associated with schizophrenia. Current medications ameliorate some symptoms of the disease (hallucinations, delusions, thought disorders), but are ineffective against other core symptoms (flat affect, avolition, memory and attention deficits, social withdrawal). Moreover, the side effects of current medications have limited the usefulness of these treatments. The brain KCNQ potassium channels are powerful regulators of brain network activity and, therefore, are uniquely positioned to monitor and regulate information processing and mutual interactions of brain regions implicated in pathology of schizophrenia. These channels will be studied in order to access their promise as novel brain targets for the development of therapies for the core symptoms of schizophrenia without serious side effects.
Filed on October 13, 2014.
Tell us what you know about Mohammadhossein Behnam Ghasemzadeh's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.